anatera stungulyf, lausn 10 %
alcon nordic a/s - fluoresceinum natríum - stungulyf, lausn - 10 %
sativex munnholsúði, lausn 27 mg/ml + 25 mg/ml
jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml
alcaine augndropar, lausn 5 mg/ml
alcon nordic a/s - proxymetacainum hýdróklóríð - augndropar, lausn - 5 mg/ml
mydriacyl augndropar, lausn 10 mg/ml
alcon nordic a/s - tropicamidum inn - augndropar, lausn - 10 mg/ml
oculac augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
oculac án rotvarnar augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
rekovelle
ferring pharmaceuticals a/s - follitrópín delta - anovulation - hormón kynlíf og stillum kynfæri - stjórnað eggjastokkum örvun fyrir þróun mörgum konum í konur gangast undir aðstoða æxlun tækni (list) eins og glasafrjóvgun (tÆknifrjÓvgun) eða intracytoplasmic sprauta sæði (icsi) hringrás.
prid delta leggangainnlegg 1,55 g
ceva santé animale* - progesteronum inn - leggangainnlegg - 1,55 g
vidprevtyn beta
sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - bóluefni - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 og 5. 1 in product information document). notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.
vigamox (moxifloxacin alcon) augndropar, lausn 5 mg/ml
novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml